Contributions
Abstract: PB2228
Type: Publication Only
Background
Umbilical cord blood plasma(UCBP) is separated from umbilical cord blood. UCBP contains a variety of hematopoietic growth factors which can stimulate hematopoiesis.
Aims
The aim of this work is to explore the influence of UCBP infusion on blood cell recovery in patients with acute leukemia undergoing chemotherapy.
Methods
Patients with the diagnosis of acute leukemia were included in this study and they were randomly distributed to experimental group and control group. Patients in experimental group received infusion of 100ml UCBP with the same ABO and Rh blood type every day after chemotherapy for five days and patients in control group received placebo for the same time. Blood routine were tested every day until WBC >4.0×109/L and PLT >20×109/L.
Results
25 patients were included in the study of which 23 were brought into statistics. 13 patients were in experimental group and 10 in control group. There were no difference in age, gender and dose intensity of chemotherapy between the two groups (P>0.05). The average recovery time of the blood neutriphil granulocyte > 0.5×109/L in experimental group and control group were respectively (8.53± 3.26) days versus (12.92± 4.75) days (P<0.05) and that of PLT >20×109/L was respectively (9.24± 3.68 ) days versus (13.15± 5.76) days (P<0.05). No UCBP transfusion-related side effects were found.
Conclusion
UCBP administration is safe as treatment for cytopenia and could promote blood cell recovery in patients with acute leukemia undergoing chemotherapy.
Session topic: 30. Transfusion medicine
Keyword(s): acute leukemia
Abstract: PB2228
Type: Publication Only
Background
Umbilical cord blood plasma(UCBP) is separated from umbilical cord blood. UCBP contains a variety of hematopoietic growth factors which can stimulate hematopoiesis.
Aims
The aim of this work is to explore the influence of UCBP infusion on blood cell recovery in patients with acute leukemia undergoing chemotherapy.
Methods
Patients with the diagnosis of acute leukemia were included in this study and they were randomly distributed to experimental group and control group. Patients in experimental group received infusion of 100ml UCBP with the same ABO and Rh blood type every day after chemotherapy for five days and patients in control group received placebo for the same time. Blood routine were tested every day until WBC >4.0×109/L and PLT >20×109/L.
Results
25 patients were included in the study of which 23 were brought into statistics. 13 patients were in experimental group and 10 in control group. There were no difference in age, gender and dose intensity of chemotherapy between the two groups (P>0.05). The average recovery time of the blood neutriphil granulocyte > 0.5×109/L in experimental group and control group were respectively (8.53± 3.26) days versus (12.92± 4.75) days (P<0.05) and that of PLT >20×109/L was respectively (9.24± 3.68 ) days versus (13.15± 5.76) days (P<0.05). No UCBP transfusion-related side effects were found.
Conclusion
UCBP administration is safe as treatment for cytopenia and could promote blood cell recovery in patients with acute leukemia undergoing chemotherapy.
Session topic: 30. Transfusion medicine
Keyword(s): acute leukemia